

ASX Announcement

Imugene to present at 42nd Annual J.P. Morgan Healthcare Conference

Sydney, Australia, 11 December 2023: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce it has been invited to present at the 42nd Annual J.P. Morgan Healthcare Conference.

The conference is being held 7-11 January 2024 at The Westin St. Francis in San Francisco, California, USA. Imugene's CEO Leslie Chong will present at 2:30pm Pacific time on Tuesday 9 January 2024 (9:30am AEDT, Wednesday 10 January 2024).

Interested parties can listen via the following webcast details, noting this is an audio only broadcast with slides to be available at the link that will require control by the listener:

https://jpmorgan.metameetings.net/events/healthcare24/sessions/49650-imugene-ltd/webcast?gpu_only=true&kiosk=true

The J.P. Morgan Healthcare Conference is one of the largest and most prestigious events on the healthcare and biotechnology industry calendar each year, with more than 8,000 investors, senior industry professionals and government officials in attendance at the 2023 event.

Imugene MD & CEO, Ms Leslie Chong said: "This is the second year we have been invited to speak at the J.P. Morgan Healthcare Conference which is a major honour and rare for an Australian biotechnology company. Following an exciting year for Imugene in 2023, we're looking forward to showcasing our technology, including our recently acquired azer-cel platform, to a global audience at the event."

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com



Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

Join us on InvestorHub; IMU.investorhub.com

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies



will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.